Practice guideline update summary: Mild cognitive impairment [RETIRED]
Ronald C. Petersen, Oscar L. López, Melissa J. Armstrong et al.
Research Article — Peer-Reviewed Source
Original research published by Petersen et al. in Neurology. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Clinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).
Full text is available at the publisher.
Read at Publisher| DOI | 10.1212/wnl.0000000000004826 |
| Journal | Neurology |
| Year | 2017 |
| Authors | Ronald C. Petersen, Oscar L. López, Melissa J. Armstrong, Thomas S.D. Getchius, Mary Ganguli, David Gloss, Gary Gronseth, Daniel Marson, Tamara Pringsheim, Gregory S. Day, Mark A. Sager, James C. Stevens, Alexander Rae‐Grant |
| License | Open Access — see publisher for license terms |
| Citations | 2,109 |